Share on StockTwits

Myriad Genetics (NASDAQ:MYGN) is scheduled to issue its Q414 quarterly earnings data on Tuesday, August 12th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $187.68 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Myriad Genetics (NASDAQ:MYGN) opened at 37.74 on Monday. Myriad Genetics has a 52 week low of $20.02 and a 52 week high of $42.50. The stock has a 50-day moving average of $37.65 and a 200-day moving average of $35.79. The company has a market cap of $2.824 billion and a P/E ratio of 15.83.

MYGN has been the subject of a number of recent research reports. Analysts at SunTrust raised their price target on shares of Myriad Genetics from $22.00 to $26.00 in a research note on Monday, July 14th. On the ratings front, analysts at RBC Capital raised their price target on shares of Myriad Genetics from $31.00 to $40.00 in a research note on Monday, June 30th. They now have a “sector perform” rating on the stock. Finally, analysts at Macquarie reiterated a “neutral” rating on shares of Myriad Genetics in a research note on Thursday, June 5th. They now have a $36.00 price target on the stock, down previously from $38.00. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $35.34.

Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.